SCHEMBL23979418

SCHEMBL23979418

Cc1nc2ccc(CNC(=O)Nc3ccc(Cl)cc3)cc2c(=O)n1C1CCCC(=O)NC1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 8/20 0.49
CRBN Q96SW2 8/20 0.49
GSPT1 P15170 4/20 0.46
IKZF3 Q9UKT9 1/20 0.46
LMNA P02545 4/20 0.45
KDM4E B2RXH2 2/20 0.45
ALDH1A1 P00352 2/20 0.45
NPSR1 Q6W5P4 2/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 2/20 0.42
MAPT P10636 3/20 0.41
ERCC1 P07992 1/20 0.41
ERCC4 Q92889 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
GAA P10253 2/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3653674 0.95 DDB1 (0.55) DDB1CRBNGSPT1IKZF3LMNA
SCHEMBL23979467 0.90 DDB1 (0.50) DDB1CRBNGSPT1IKZF3LMNA
SCHEMBL12638510 0.89 DDB1 (0.45) DDB1CRBNGSPT1IKZF3LMNA
SCHEMBL23979382 0.88 DDB1 (0.51) DDB1CRBNGSPT1IKZF3KDM4E
SCHEMBL23979396 0.88 DDB1 (0.47) DDB1CRBNGSPT1IKZF3LMNA
SCHEMBL23980077 0.88 DDB1 (0.45) DDB1CRBNGSPT1IKZF3LMNA
SCHEMBL3655629 0.87 CRBN (0.62) DDB1CRBNGSPT1IKZF3
SCHEMBL23980066 0.85 DDB1 (0.54) DDB1CRBNIKZF3LMNAKDM4E
SCHEMBL18815287 0.85 DDB1 (0.53) DDB1CRBNGSPT1IKZF3
SCHEMBL3654992 0.85 DDB1 (0.56) DDB1CRBNGSPT1IKZF3LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same SALARIUS PHARMACEUTICALS, INC. (US) 2023-10-03 US disclosed
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME SALARIUS PHARMACEUTICALS, INC. 2021-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773080-B2 Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885GSPT1 4580/4885
US-20210340125-A1 DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME HPGDS, HPGD, AQP3 DDB1 690/4885CRBN 1079/4885GSPT1 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.